Extended Interval Dosing with Ocrelizumab in Multiple Sclerosis
MULTIPLE SCLEROSIS JOURNAL(2024)
Key words
Multiple sclerosis,anti-CD20,ocrelizumab,treatment interval,NEDA-3,biomarkers,neuroimaging,personalized medicine,extended dosing
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined